CytoLynx Therapeutics Funding: $45M Raised, Series A (2021)
CytoLynx Therapeutics has raised $45M in total funding. Latest round: Series A. Backed by TF Capital, YF Capital, BioTrack Capital.
CytoLynx Therapeutics funding overview
CytoLynx Therapeutics has raised $45M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in September 2021. The round record for CytoLynx Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include TF Capital, YF Capital, BioTrack Capital, Ruihua Capital, TG Sino-Dragon Fund, TigerMed. 6 distinct backers are named across the disclosed rounds.
Frequently asked about CytoLynx Therapeutics funding
How much has CytoLynx Therapeutics raised?
CytoLynx Therapeutics has raised $45M in total disclosed funding across the rounds on record.
Who has invested in CytoLynx Therapeutics?
TF Capital, YF Capital, BioTrack Capital, Ruihua Capital, TG Sino-Dragon Fund, TigerMed are named among the investors backing CytoLynx Therapeutics.
What was the latest CytoLynx Therapeutics funding round?
The most recent disclosed round is a Series A, announced in September 2021.
Where is CytoLynx Therapeutics based?
No headquarters location is disclosed for CytoLynx Therapeutics.
When did CytoLynx Therapeutics last raise?
The last disclosed CytoLynx Therapeutics round closed in September 2021 at Series A.
Round data for CytoLynx Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies and backer lists below.
